Method and composition for reducing E. coli disease and enhancing performance

ABSTRACT

Bacillus  strains that inhibit pathogenic swine  E. coli  and/or improve performance are provided. Inhibition of pathogenic swine  E. coli  decreases  E. coli  disease. At least one strain enhanced swine performance by improving average daily gain, feed efficiency, and feed intake. Preferred  Bacillus  strains are of species that are included on the GRAS list.  Bacillus  species are sporeformers and therefore are highly stable and can be fed to swine.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority under 35 U.S.C. §119(e) to U.S.Provisional Patent Application No. 60/571,193, filed May 14, 2004, theentirety of which is incorporated by reference herein.

BIBLIOGRAPHY

Complete bibliographic citations of the references referred to herein bya reference numeral in parentheses can be found in the Bibliographysection, immediately following the Examples.

FIELD OF THE INVENTION

The invention relates to bacterial strains and the use thereof tocontrol disease in animals and enhance animal performance. Moreparticularly, the invention relates to Bacillus strains and their use tocontrol diseases caused by Escherichia coli and to enhance animalperformance.

BACKGROUND OF THE INVENTION

E. coli disease is an important and devastating disease to swineproducers. Known for causing edema disease (ED) and post weaningdiarrhea (PWD), the economic impact can be substantial with death lossesas high as 50% (1). Multiple management and environmental factors havebeen associated with E. coli infections, including age at weaning, diet,crowding, and transportation. Certain host genetic factors, such ashaving receptors for the E. coli fimbriae to attach to the intestinalsurface, also contribute to a pig's susceptibility to E. coli infection.

ED and PWD are both caused primarily by hemolytic E. coli proliferatingin the small intestine. E. coli infection can also be diagnosed in pigsshortly after birth to two weeks of age (3). ED can occur in pigsbetween three and eight weeks of age and is characterized bysubcutaneous and subserosal edema, a progressive ataxia, paralysis and ahigh mortality (2). PWD is commonly observed at 7-10 days post weaningbut can occur up to eight weeks of age and is characterized by reducedgrowth rate, severe diarrhea, dehydration, toxemia, or death (2, 3).

Both PWD and ED can occur in the same group of pigs and the causative E.coli strains often share certain virulence factors. Usually the firstmanifestation seen with PWD is sudden death, as early as two days, afterweaning. Pigs that do not die suddenly, display a decrease of feedconsumption and watery diarrhea which leads to depression and lifethreatening dehydration. Many pigs show cyanotic discoloration of thetip of the nose, the ears, and the abdomen. Staggering and uncoordinatedmovements may also be seen in severely affected pigs. Peak mortalitygenerally occurs 6-10 days after weaning. In a herd with PWD, morbiditycan vary. Within a litter, the morbidity may be high and reach up to 80%with an average of 30-40%. Mortality in untreated herds can reach 26%(4).

Anorexia is often the first sign seen with edema disease. If diarrhea isto occur, it usually follows after the anorexia. The diarrhea usuallydisappears by the time the edema and nervous involvement becomeapparent. Edema can be seen in the eyelids, forehead, ears, and lips.Upon necropsy edema can be seen in the submucosa of the stomach, themesocolon, gallbladder, and lungs. Progressive ataxia and mentalconfusion leading to complete recumbence and severe dyspnea are seen inthe final stages. The mortality rate in edema disease can reach 50% toover 90% (4).

The source of E. coli in a weanling pig is usually derived from theenvironment either in the nursery, or the pig may acquire the E. coli inthe farrowing unit and carry it into the nursery. Pathogenic E. coli canspread by means of aerosol, feed, farm vehicles, pigs, and other animals(4).

E. coli are part of the normal intestinal flora in pigs. Most of theintestinal E. coli do not possess the ability to cause disease. These E.coli pass through the intestines and are not able to attach to theintestinal wall and do not produce toxins. Those E. coli that arepathogenic and cause disease have the ability to do so because they haveobtained genes which code for specific virulence factors (5). Thesevirulence factors allow the E. coli to adhere to the intestinal wall,colonize the intestine, and produce enterotoxins, which can causediarrhea and verotoxins which can cause edema disease.

Enterotoxigenic E. coli (ETEC) is the major type of E. coli implicatedin diarrheal disease of pigs (FIG. 1) (5). These strains arecharacterized by their ability to adhere to the pig intestine andproduce enterotoxins. Adherence to the intestinal tract is performed byfrimbriae (pili) on the bacteria that attach to receptors located on theintestinal surface. These pili are highly antigenic filamentous proteinstructures that extend from the surface of the bacteria (5). The majorpili found on ETEC are F4 (K88), F5 (K99), F6 (987p), F41, and F18.

Enterohemorrhagic E. coli (EHEC) is the major type of E. coli implicatedin edema disease of pigs. The basis of colonization and toxin productionis the same as with the ETEC. The only pilus that has been associatedwith edema disease in swine is F18, with the F18ab variant beingassociated more commonly with edema disease. The toxin produced by theEHEC is known as Stx2e. This toxin belongs to a family of toxins calledshiga toxins or verotoxins. It is a high molecular weight protein thatbinds to specific receptors on vascular endothelial cells in certaintarget tissues (5). Therefore, the disease seen with EHEC is a result oftoxemia. The receptor for the toxin is found in blood vessels in thebrain, eyelid, stomach wall, mesentery of the colon, and the spinal cord(5). The toxin causes injury and death to the endothelial cells in thesetarget organs.

Enteropathogenic E. coli (EPEC) strains, also known as attaching andeffacing E. coli (AEEC) may play a role in diarrheal disease of pigs.These strains have only recently been investigated as a cause ofdiarrhea in weaned pigs and were first associated with diarrhea inhumans (5). The EPEC cause disease by forming an attachment to the pigintestinal epithelial cells, possibly through the use of pili, and causedestruction of the microvilli (5). The lesions are called attaching andeffacing lesions.

No universally effective prophylaxis is available for post weaning E.coli disease (4). Fundamental to the prevention of disease is to preventvillous atrophy and colonization (7). Villous atrophy and colonizationare related to many factors such as rotavirus infection, diet, STb, andstress (7). Managerial factors that contribute to stress are changes intemperature, overcrowding, feed changes, humidity, and mixing of pigs.

No vaccines are currently commercially available for post weaning E.coli disease. However, there are companies that will prepare for eachfarm a killed or modified live vaccine using one attenuated strain ofpathogenic E. coli found on the farm. This vaccine generally containsF18 or K88 pili but lacks the toxin genes. The attenuated strain isoften grown on the farm and fed or given intranasal to pigs. Toxoidsmade from Stx2e are also used, but again are not commercially available.These vaccines are often not very pure and even though they may impactmortality due to E. coli disease, they generally do not decreasemortality to acceptable levels.

Egg immunoglobin, produced by hens that were vaccinated against fimbrialE. coli antigens, have also been developed as an antibody-containing eggpowder in pig feed (4). The egg immunoglobin is produced by vaccinatingthe hen with an attenuated strain of ETEC or with fimbriae from thepathogenic E. coli strains. The egg yolks are then collected, and eggyolk antibody powder is then obtained by freeze drying the water solubleprotein fraction of egg yolks (9). The theory was that it would provideimmune protection against colonization with K88 and F18 positive E. coli(4). Marquardt et al. showed that egg-yolk antibodies were able toprevent experimentally induced ETEC diarrhea in 3 day old and 21 day oldweaned pigs, and also decreased the occurrence of diarrhea inearly-weaned pigs during a field trial study (9). Nevertheless, this isnot always what is seen in the field, and producers seem to get mixedresults using egg-yolk antibodies. What has been shown is thatprotection is only provided against challenge strains that have only theF18 fimbriae in common with the vaccine strains (4). Protection may alsooccur only for the strain of E. coli the hen was vaccinated for. Anotherdrawback is that egg immunoglobin can be expensive to include in pigdiets.

Some pigs are genetically resistant to ETEC and EHEC strains becausethey genetically lack the K88 and/or F18 pili receptor. Breeding forgenetic resistance can help control E. coli disease. The difficult partabout this process is the expense of testing and lack of testsavailable. A proprietary test for the presence of F18 receptors has beendeveloped, but no test exists for the K88 receptor (6).

Antibiotics are often added to feed as a preventative. There are manydrawbacks such as consumer acceptance and selection of resistantbacteria (4). Numerous antimicrobial substances are used for thispurpose; some include: sulfonamide, trimethoprim, gentamicin, and otheraminoglycosides. Isolates from ETEC and EHEC show the highest rate ofresistance within swine E. coli, and this resistance is often inducedwithin days or a few weeks (4).

Zinc oxide and spray dried porcine plasma included in weanling pig dietshave also been used with mixed success.

Once an E. coli outbreak occurs, treatment must be administered todecrease mortality and morbidity. Antimicrobial therapy has been thetreatment of choice. Antibiotics can be given parenterally or in thewater once disease is detected. Antibiotic resistance with E. coliisolates is widely known. Pathogenic E. coli resistance has beendetected against every antibiotic approved for use (4). Electrolytes canalso be offered as a treatment choice but can be very costly to theproducer.

One important factor that could result in the failure of currenttreatment and prevention techniques is the high genetic diversity ofETEC and EHEC strains. A high degree of heterogeneity has been shownamong isolates from the same state and farm (8). Wilson, et al showedthat serotypes associated with post-weaning diarrhea appear to belimited but have very diverse genetic backgrounds (10). This leads oneto believe that multiple strains of the same virulence factors orserotype are the cause for a single outbreak of E. coli disease on afarm. The cause of heterogeneity is uncertain, but may be due to thefact that gene transfer can readily occur within swine E. coli. The factthat antibiotics, vaccines, and other treatments are always being usedinstigates the need of gene transfer for the survival of pathogenicswine E. coli. In addition, the great amount of fecal oral transmissionin swine systems provides an environment needed for gene transfer tooccur. This heterogeneity is evidence to explain why many traditionalmethods of treatment and prevention fail.

Therefore, what is needed is one or more isolated Bacillus microorganismthat is capable of at least one of (A) inhibiting E. coli disease and(B) improving performance of an animal. A method of feeding swine one ormore of the above-referenced Bacillus microorganisms to inhibit E. colidisease and/or improve performance of the swine is also needed.Additionally needed is a method of forming a direct-fed microbial fromthe above-referenced Bacillus microorganisms.

SUMMARY OF THE INVENTION

The invention, which is defined by the claims set out at the end of thisdisclosure, is intended to solve at least some of the problems notedabove. Provided is an isolated microorganism of the genus Bacillus thatis capable of at least one of the following: (A) inhibiting E. colidisease and (B) improving performance of an animal. In one embodiment,the microorganism is selected from the group consisting of strains3A-P4, 15A-P4, and 22C-P1. In another embodiment, the microorganism isstrain 15A-P4. A combination of microorganisms comprising at least twoof the above-listed microorganisms is also provided.

Additionally provided is a method of feeding swine. In the method, atleast one of the above-listed strains is fed to the swine. A method offorming a direct-fed microbial including at least one of theabove-listed strains is also provided. In the method at least one of theabove-listed strains is grown in a liquid nutrient broth. Themicroorganism is separated from the liquid to form the direct-fedmicrobial.

BRIEF DESCRIPTION OF THE DRAWINGS

Preferred exemplary embodiments of the invention are illustrated in theaccompanying drawings in which:

FIG. 1 is a diagram showing colonization and disease due toEnterotoxigenic E. coli (ETEC), Enteropathogenic E. coli (EPEC), andEnterohemorrhagic E. coli (EHEC).

FIG. 2 is a dendogram of the E. coli isolates obtained from thediagnostic laboratory combining the RAPD analysis using primer 1 andprimer 2. Also shown is the multiplex results reported from a diagnosticlaboratory and the multiplex results obtained from Agtech Productslaboratory.

FIG. 3 is a gel image of two sets of DNA fingerprints for threepreferred strains of Bacillus isolates: 3A-P4 (lanes 1 and 5), 15A-P4(lanes 2 and 6), and 22C-P1 (lanes3 and 7). A 100 bp molecular weightmarker (Bio-Rad, Hercules, Calif.) is in lane 4. Two different 10 bpprimers were used for two sets of random amplified polymorphic DNAanalysis on the isolates, with results of the first set shown in lanes1-3, and results of the second set shown in lanes 5-7.

FIG. 4 is a graph showing percent inhibition of E. coli strain E.20 byBacillus isolate 3A-P4 at different optical density (OD) readings.

FIG. 5 is a graph showing percent inhibition of E. coli strain E.20 byBacillus isolate 15A-P4 at different OD readings.

FIG. 6 is a graph showing percent inhibition of E. coli strain E.20 byBacillus isolate 22C-P1 at different OD readings.

FIG. 7 is a graph showing percent inhibition of E. coli strains E.20 andE.23 by Bacillus isolate 3A-P4 at different time points.

FIG. 8 is a graph showing percent inhibition of E. coli strains E.20 andE.23 by Bacillus isolate 15A-P4 at different time points.

FIG. 9 is a graph showing percent inhibition of E. coli strains E.20 andE.23 by Bacillus isolate 22C-P1 at different time points.

FIG. 10 is a graph showing growth curves, in the absence of any Bacillusisolate, of E. coli strains E.20 and E.23 at different time points.

FIG. 11 is a SDS-PAGE on 15A-P4 after ammonium sulfate precipitation.P=pellet fraction, S=supernatant fraction. The box outlines thesuspected inhibitory protein located between the 31,000 and 45,000molecular weight marker. The (+) denotes inhibition of E. coli using thespot plate method. The (−) denotes no inhibition of E. coli using thespot plate method.

FIGS. 12A and 12B are the graphs showing the mode of action of theactive metabolite produced by 3A-P4 on E. coli strain E.20 (FIG. 12A)and E. coli strain E.23 (FIG. 12B).

FIGS. 13A and 13B are the graphs showing the mode of action of theactive metabolite produced by 15A-P4 on E. coli strain E.20 (FIG. 13A)and E. coli strain E.23 (FIG. 13B).

FIGS. 14A and 14B are graphs showing the mode of action of the activemetabolite produced by 22C-P1 on E. coli strain E.20 (FIG. 14A) and E.coli strain E.23 (FIG. 14B).

FIGS. 15A and 15B are graphs showing the effect of a preferredembodiment of a combination of Bacillus strains (Product 3) on pigweight for Field Trial E at Day 7 (FIG. 15A) and Day 15 (FIG. 15B).

FIG. 16 is a graph showing the effect of Product 3 on ADG for FieldTrial E.

FIG. 17 is a graph showing the effect of Product 3 on feed intake forField Trial E.

FIGS. 18A and 18B are graphs showing the effect of Product 3 onmortality for Field Trial E at Days 0-7 (FIG. 18A) and Days 0-28 (FIG.18B).

FIG. 19 is the multiplex results of Field Trial E.

Before explaining embodiments of the invention in detail, it is to beunderstood that the invention is not limited in its application to thedetails of construction and the arrangement of the components set forthin the following description or illustrated in the drawings. Theinvention is capable of other embodiments or being practiced or carriedout in various ways. Also, it is to be understood that the phraseologyand terminology employed herein is for the purpose of description andshould not be regarded as limiting. The references cited throughout theapplication are incorporated by reference herein.

DETAILED DESCRIPTION DEFINITIONS

The following definitions are intended to assist in providing a clearand consistent understanding of the scope and detail of the terms:

As used herein, “active metabolite” means a substance produced bybacteria and which has antibacterial activity towards other genuses ofbacteria.

As used herein, “animal” means a multicellular organism of the kingdomAnimalia.

As used herein, “bacteriocin” means a substance produced by bacteria andwhich has antibacterial activity towards other genuses of bacteria.

As used herein “basemix” or “concentrated basemix” refers to Bacillusstrains added to a carrier to make a basemix form. The concentrated formis composed of the Bacillus strains added the carrier in a moreconcentrated form. The basemix or concentrated basemix forms are then beadded to the feed at a desired inclusion rate and fed to the animal.

As used herein, “performance” refers to the growth of an animal, such asa pig, measured by the following parameters: average daily gain (ADG),weight, mortality, feed conversion, which includes both feed:gain andgain:feed, and feed intake.

“An improvement in performance” as used herein, means an improvement inat least one of the parameters listed above under the performancedefinition.

In accordance with the present invention there may be employedconventional molecular biology and microbiology within the skill of theart. Such techniques are explained fully in the literature. See, e.g.,Sambrook, Fritsch & Maniatis, Molecular Cloning: A Laboratory Manual,Third Edition (2001) Cold Spring Harbor Laboratory Press, Cold SpringHarbor, N.Y.

Aerobic and facultative sporeformers of the genus Bacillus wereisolated. Bacillus species are the only sporeformers that are consideredGRAS, i.e., generally recognized as safe. In a preferred embodiment, aBacillus species was included only if it had GRAS status. The Bacillusspecies were isolated from environmental samples such as poultry litterand animal waste and screened. Other sources of Bacillus can also bescreened. The Bacillus strains were screened for their ability toinhibit growth of pathogenic swine E. coli. Although not intended to bea limitation to the present disclosure, it is believed that inhibitionis accomplished via the secretion of an active metabolite from theBacillus. While applicants do not wish to be restricted to a particulartheory of how the active metabolite inhibits microbial growth and do notintend to limit the present disclosure, it is believed that the activemetabolite is a proteinaceous substance and, more specifically, it isbelieved to be a bactericidal.

The Bacillus isolates were tested for their ability to inhibit variouspathogenic strains of swine E. coli. The E. coli strains were obtainedfrom animal diagnostic laboratories, swine environment, and fecalmatter. The E. coli strains were shown to be pathogenic by performingmultiplex PCR to detect pili and toxin genes associated with pathogenicE. coli disease in swine. To test for production of active metabolite,Bacillus isolates were replica plated onto pathogen indicator plates,which were formed from a 1% pathogen inoculum of a pathogenic swine E.coli strain.

Additionally, the active metabolite activity of the Bacillus isolateswas reconfirmed using a spot assay method. The Bacillus isolates werethen tested using appropriate biochemical tests to determine whether theisolates had GRAS status.

The spectrum of activity of the various Bacillus isolates was thendetermined. The Bacillus isolates were tested for activity against theknown swine E. coli pathogens collected from different regions of theUnited States using the spot assay method. This was done to confirm thatthe activity produced by the Bacillus isolates would be usefulthroughout the United States. The Bacillus isolates that showed thehighest inhibitory activity against numerous pathogenic E. coli strainswere further characterized for their activity level.

From these experiments, three preferred Bacillus strains were found:3A-P4, 15A-P4, and 22C-P1, although other strains can also be used.These strains were preferred because of the number of pathogenic E. colistrains that each inhibited and because of their GRAS status. On Jan.12, 2005, strains 3A-P4, 15A-P4, and 22C-P1 were deposited at theAmerican Type Culture Collection, 10801 University Blvd., Manassas, Va.20110-2209 and given accession numbers PTA-6506 (3A-P4), PTA-6507(15A-P4), and PTA-6508 (22C-P1). The deposits were made under theprovisions of the Budapest Treaty on the International Recognition ofthe Deposit of Microorganisms for the Purposes of Patent Procedure.

Strains 3A-P4, 15A-P4, and 22C-P1, can be fed individually or incombination, to swine, although other strains are included within thescope of the invention. For the Bacillus strains 3A-P4, 15A-P4, and22C-P1, growth times were determined for production of an optimal levelof the active metabolite using the broth activity method. The assayincubation time at which optimal inhibition of E. coli occurred was alsodetermined using the broth activity method. For this, active metabolitewas added to a culture of E. coli and ODs were read at various timepoints. The Bacillus isolates 3A-P4, 15A-P4, and 22C-P1 were tested foractivity against 142 known swine E. coli pathogens collected fromdifferent regions of the United States using the broth activity method.These strains inhibited to varying degrees one hundred percent of the E.coli strains tested. The strains can be used alone or in combination toinhibit growth of pathogenic swine E. coli.

The three preferred Bacillus isolates of the invention were isolatedfrom different geographical regions of North America and from differentenvironmental sources. Specifically, strain 3A-P4 was isolated fromchicken litter from Canada, strain 15A-P4 was isolated from turkeylitter from the Western United States, and strain 22C-P1 was isolatedfrom a swine lagoon from the Eastern United States.

The active metabolite was then purified from each of the Bacillusisolates to two levels: first, a crude purification of the activemetabolite was obtained by filtering the culture supernatant, andsecond, a partially purified active metabolite was obtained by saltingout the active metabolite and then fractionating it by columnchromatography. The stability and characterization of the activemetabolite was then determined using the crude form of the activemetabolite by performing enzyme and heat degradation assays, mode ofaction assays, and antibiotic sensitivity assays. Optimal media and timeconditions were also determined for cell growth and spore formation.

Further characterization of the Bacillus isolates 3A-P4, 15A-P4, and22C-P1 was performed, including DNA fingerprinting and determiningstability of the isolates in a swine premix at 60° C. for 8 weeks.

Through field trial studies, it was determined that the Bacillus strainsalso enhance nursery swine performance. Therefore, it is economical fora producer to routinely include the Bacillus strains, eitherindividually or in combination, in feed not only to prevent E. colidisease but also to enhance performance.

The Bacillus isolates of the invention, which inhibit pathogenic E.coli, can be directly fed to swine to inhibit pathogenic swine E. colidisease and to enhance swine performance. Feeding microorganisms thathave GRAS status to livestock is an acceptable practice amongstproducers, veterinarians, and others in the livestock industry. Byinhibiting this pathogen in the swine, the Bacillus isolates reduces andeven prevents E. coli disease in swine.

The Bacillus isolates can be administered as a preventative toswineherds not currently infected with pathogenic E. coli. In apreferred embodiment, newly weaned pigs are fed the Bacillus isolatesthroughout the nursery phase to inhibit or even prevent outbreaks of E.coli disease and to enhance performance. However, one or more Bacillusisolate can be fed at other phases also. Routine administration of themicroorganisms dramatically reduces and even eliminates outbreaks of E.coli disease at animal production facilities and enhances swineperformance.

The Bacillus isolates can be administered as a direct-fed microbial.Administration of one or more direct-fed microorganisms to animals isaccomplished by any convenient method, including adding the Bacillusisolates to the animals' drinking water or to their feed, or by directoral insertion. In a preferred embodiment, the microorganism is fed toanimals by adding it to the animals' feed or water. Bacillus isolatespreferably are administered as spores.

The Bacillus isolates may be presented in various physical forms, forexample as a top dress, liquid drench, gelatin capsule, gel, or added tothe water. In feed form, the isolates may be presented in a form as abasemix or a concentrated form of the basemix. In a preferred embodimentof a top dress form, freeze-dried Bacillus fermentation product is addedto a carrier, such as whey, maltodextrin, sucrose, dextrose, limestone(CaCO₃), rice hulls, yeast culture, dried starch, or sodium silicoaluminate.

In a preferred embodiment of the liquid drench form, freeze-driedBacillus fermentation product is added to a carrier, such as whey,maltodextrin, sucrose, dextrose, dried starch, or sodium silicoaluminate, and a liquid is added to form the drench.

In a preferred embodiment of the gelatin capsule form, freeze-driedBacillus fermentation product is added to a carrier, such as whey,maltodextrin, sugar, limestone (CaCO₃), rice hulls, yeast culture driedstarch, or sodium silico aluminate. The Bacillus isolates and carriercan be enclosed in a gastrointestinal-degradable gelatin capsule.

In a preferred embodiment of the gel form, freeze-dried Bacillusfermentation product is added to a carrier, such as vegetable oil,sucrose, silicon dioxide, polysorbate 80, propylene glycol, butylatedhydroxyanisole, and citric acid, or artificial coloring to form the gel.In a preferred embodiment of the water form, the freeze-dried Bacillusfermentation product is added to a carrier, such as sucrose, dextrose,sodium silico aluminate, and artificial coloring.

In a preferred embodiment of the basemix or concentrated basemix form,the freeze-dried Bacillus fermentation product is added to a carrier,such as, but not limited to, rice hulls, dried brewers grain, limestone,or baylith for moisture control. Other carrier that are suitable andcompatible for these strains can also be used.

The microorganisms can be administered as spray-dried, freeze-dried,fluidized bed dried, used in a solid state fermentation form, as well asother forms. For freeze drying, the wet cell paste preferably is thenmixed with cryoprotectants, which maintain the viability of the cellsduring the freezing and drying process. The mixture is then placed intrays, frozen and subsequently dried. For spray drying, the paste orslurry is then mixed with spray drying aids, if applicable, and spraydried. The resulting dried cake, obtained from drying methods or solidstate fermentation method, is then milled to a uniform size and platedto determine the activity. After a viable cell count has beendetermined, the cell count preferably is standardized to a predeterminedactivity level or colony forming units (CFU) per gram by blending withdry carriers.

To produce the Bacillus isolates, one or more isolates are grown in aliquid nutrient broth, such as TSB, preferably to a level at which thehighest number of spores are formed. In a preferred embodiment, theisolates are grown to an OD where the spore yield is at least 1×10⁹colony forming units (CFU) per ml of culture. The bacterial strains ofthe present invention are produced by fermentation of the bacterialstrains. fermentation is started by scaling-up a seed culture. Thisinvolves repeatedly and aseptically transferring the culture to a largerand larger volume to serve as the inoculum for the fermentation, whichis carried out in large stainless steel fermentors in medium containingproteins, carbohydrates, and minerals necessary for optimal growth. Anon-limiting exemplary medium is TSB. After the inoculum is added to thefermentation vessel, the temperature and agitation are controlled toallow maximum growth. Once the culture reaches a maximum populationdensity, the culture is harvested by separating the cells from thefermentation medium. This is commonly done by centrifugation. The countof the culture can then be determined.

The count of the bacteria is important when combined with a carrier. Atthe time of manufacture of the composition, the Bacillus countpreferably is at least about 1.0×10¹¹ CFU/g. The counts may be increasedor decreased from these base numbers and still have complete efficacy.CFU or colony forming unit is the viable cell count of a sampleresulting from standard microbiological plating methods. The term isderived from the fact that a single cell when plated on appropriatemedium will grow and become a viable colony in the agar medium. Sincemultiple cells may give rise to one visible colony, the term colonyforming unit is a more useful unit measurement than cell number.

To prepare the compositions, the cultures and the carrier can be addedto a ribbon or paddle mixer and mixed preferably for about 15 minutes.The components are blended such that a uniform mixture of the carrierand cultures result. The final product is preferably a dry flowablepowder. Exemplary carriers in this composition are rice hulls, driedbrewers grain, limestone, baylith, or other suitable carriers formicroorganisms.

The preferred dosage range of the liquid drench, gelatin capsule, andgel is about 1×10⁴ CFU/g or ml/day to about 1×10¹⁰ CFU/g or ml/day, andmore preferably about 1×10⁶ CFU/g or ml/day. The preferred dosage rangeof the top dress, basemix, and premix is about 1×10³ CFU/g of feed toabout 1×10⁸ CFU/g of feed, and more preferably about 1×10⁶ CFU/g offeed. The preferred dosage range for inclusion into water is about 1×10³CFU/pig/day to about 1×10¹⁰ CFU/pig/day, and more preferably about1×10⁸. CFU/pig/day. While these examples use freeze-dried Bacillus as aningredient in the top dress, liquid drench, gelatin capsule, gels,water, and feed forms it is not necessary to freeze-dry the Bacillusbefore feeding it to swine. For example, spray-dried, fluidized beddried, or solid state fermentation Bacillus or Bacillus in other statesmay be used. The microorganisms can also be administered in a wet cellslurry paste, with or without preservatives, in concentrated,unconcentrated, or diluted form.

The composition used in the Examples below was produced as follows:strain 3A-P4 with a count of 7×10¹¹ CFU/g, 15A-P4 with a count of8.4×10¹¹ CFU/g, and 22C-P1 with a count of 6×10¹¹ CFU/g were combined indifferent ratios with carriers to determine the best ratio to inhibitpathogenic swine E. coli and enhance nursery performance. Thecombinations were as follows: Product 1: 30% of the total count ofstrain 3A-P4, 60% of the total count of strain 15A-P4, 10% of the totalcount of strain 22C-P1 for a final bacteria count of 5.1×10⁸ CFU/g;Product 2: 100% of the total count of strain 22C-P1 with a finalbacteria count of 4.5×10⁸ CFU/g; and Product 3: 90% of the total countof strain 22C-P1, 10% of the total count of strain 15A-P4 with a finalbacteria count of 5.1×10⁸ CFU/g. In the Examples, all the abovecombinations were added to the feed for a final count of 1×10⁶ CFU/g offeed and were fed throughout the nursery phase. Carriers used in allcombinations used in the experiments were 40% rice hulls, 19% driedbrewers grain, 40% limestone, and 1% baylith for moisture control. Apreferred combination is 90% of the total count of strain 22C-P1 and 10%of the total count of strain 15A-P4. This combination was found to beeffective in decreasing swine E. coli disease and enhancing swineperformance.

Additional combinations and single-strain compositions that are usefulinclude an about 90% of the total count of strain 15A-P4 and about 10%of the total count of strain 22C-P1 combination with a final bacteriacount of about 1×10⁶ CFU/g of feed and 100% 15A-P4 with a final bacteriacount of about 1×10⁶ CFU/g of feed.

Bacillus strains provided herein are capable of at least one of thefollowing in swine: (A) inhibiting E. Coli disease and B) improvingperformance. One or more of the Bacillus strains have been shown to beeffective for these purposes when fed to nursery pigs. It is believedthat feeding one or more Bacillus strain provided herein would also beuseful when fed to pigs at other stages in their lives. For instance, itis believed that feeding one or more Bacillus strain to breeding stock,including sows, gilts, and boars, and to lactation-phase piglets, andfinishing pigs would also provide benefits of inhibiting E. coli diseaseand/or improving performance.

One or more of the Bacillus strains has also been shown to be beneficialwhen fed to poultry. For example, populations of avian pathogenic E.coli have been reduced when strain 15-A-P4 was fed to poultry.

EXAMPLES

The following Examples are provided for illustrative purposes only. TheExamples are included herein solely to aid in a more completeunderstanding of the presently described invention. The Examples do notlimit the scope of the invention described or claimed herein in anyfashion.

Example 1 Isolation of Active Metabolite Producing Bacillus Strains andIsolation of Pathogenic Strains

A. Bacillus Strains and Media:

Microbial strains from chicken litter, turkey litter, swine waste, anddairy waste, were screened for Bacillus strains. The environmentalsample was weighed and mixed with sterile peptone blanks to make a 10⁻¹dilution. To pasteurize and, thus, to select for aerobic and facultativesporeformers, the sample was placed in a masticator for one minute andthen heated for thirty minutes in a 63° C. water bath. The sample wasthen serially plated onto Tryptic Soy Agar (TSA) and incubated at 32degrees for 24-48 hours to obtain isolates.

B. Pathogen E. coli Strains and Media:

An initial collection of pathogen strains was obtained from a swinediagnostic laboratory. This included two K88 and one F18 E. colistrains. The isolates were stored as frozen stocks at −85° C. in TSBsupplemented with 10% glycerol. For the initial screening process, thethree E. coli strains were utilized in assays to screen Bacillusisolates for activity against E. coli. Swine E. coli pathogens testedwere grown overnight in tryptic soy broth (TSB) at 37° C. A one percentinoculum was transferred into its corresponding media the next day andincubated at 37° C. until OD value at 600 nm was at 0.600.

Example 2 Activity of Bacillus Isolates Against E. coli

A. Zone of Inhibition Assay:

Activity against E. coli was determined by replica plating the Bacillusisolates onto indicator plates containing swine E. coli pathogens.Pathogen indicator plates were formed by transferring one percent of oneof the swine E. coli pathogen inoculum, grown as described above, intotempered TSA. Seven milliliters of this agar was poured into a petridish to make the pathogen indicator plates. The Bacillus isolates werereplica plated onto pathogen indicator plates and were incubatedovernight at 32° C. Plates were then observed for zones of inhibitionfor each pathogen. The Bacillus isolates that produced zones ofinhibition were picked off the plate and grown in TSB to isolate thecolony for reconfirmation of its activity. The isolates were stored asfrozen stocks at −85° C. in TSB supplemented with 10% glycerol. Thirtythousand Bacillus isolates were screened for activity against E. coli.Fifty isolates produced activity against E. coli.

B. Spot Assay:

Activity of the 50 Bacillus isolates was confirmed using the spot plateassay method by growing the isolates in TSB overnight at 32° C. Tenmicroliters of the Bacillus isolate was then spot plated onto pathogenindicator plates made as described above. Indicator plates wereincubated 24 hours at 32° C. and were observed for zones. Thirty six ofthe fifty isolates displayed activity against E. coli uponreconfirmation using the spot assay method. Table 2 shows the Bacillusstrains that had activity against one or more of the E. coli strains. Itshould be noted that some Bacillus strains had activity against morethan one E. coli strains. TABLE 2 Summary of Active Metabolite ProducingBacillus Isolates Against E. coli. POSITIVE BACILLUS INDICATOR STRAINSTRAINS Escherichia coli K88 strain BH 15 Escherichia coli K88 strain S9 Escherichia coli F18 strain 8A133 16

Example 3 Biochemical Tests on Bacillus Isolates

All Bacillus isolates that were confirmed to produce active metaboliteswere biochemical tested to identify isolates that were generallyrecognized as safe (GRAS). Testing was performed by both (1) traditionallab methods, including Gram stain, colony morphology, catalaseproduction, starch utilization, casein utilization, nitrate reduction,indole formation, Voges-Proskauer, gelatin hydrolysis, and citrateproduction and (2) an API Bacillus biochemical test kit available frombioMérieux of Hazelwood, Mo. Thirty-six Bacillus isolates were screenedusing traditional biochemical methods, which showed that six of thethirty-six isolates tested as possible GRAS strains. These isolates wereretested using the API test kit, and results showed that all sixisolates were confirmed as belonging to species that are GRAS. Theisolates producing the widest spectrum of activity against E. coli werebiochemical tested using an outside reference laboratory for finalidentification.

Example 4 Determination of Spectrum of Activity Against E. coli ofBacillus Isolates

A. Spot Plate Procedure to Determine Spectrum of Activity Against E.coli:

To confirm that the six GRAS Bacillus isolates were also effectiveagainst E. coli pathogens from other regions of the United States, abroad collection of porcine E. coli pathogens were selected from variousanimal diagnostic laboratories from Indiana, Oklahoma, Iowa, and Texas.Nineteen other GRAS Bacillus isolates that demonstrated against otherpathogens were also screened against diagnostic laboratory E. colipathogens. Some of these additional strains are included Table 4 below.

Upon arrival, pathogens were immediately grown in either TSB overnightat 37° C. Streak plates of each culture were made to ensure purecolonies, which were grown again in their respective media overnight at37° C.

Forty porcine E. coli isolates were obtained. E. coli strainsrepresented were K88, K99, 987p, F18, F41, and 718. Toxins produced bythe E. coli included the enterotoxins LT (heat-labile enterotoxin), Sta(heat-stable enterotoxin a), and STb (heat-stable enterotoxin b); andthe Shiga-like toxin Stx2e (subgroup Stx2 with variant form e).Thirty-seven of the forty E. coli isolates were confirmed as E. coliusing an API biochemical test kit.

The twenty-five GRAS Bacillus isolates, which included the six isolatesthat showed activity against the original three E. coli isolates and thenineteen isolates that showed activity against other pathogens, weretested for activity against the thirty-eight E. coli porcine pathogens,using the spot assay method described above in Example 2B. For eachBacillus isolate, an individual colony was grown overnight in TSB at 32°C. and was used as the antimicrobial producer culture.

Pathogen indicators were prepared as follows: E. coli was grown in TSBfor 24 hours at 37° C. After 24-48 hours of growth, the pathogenindicators were transferred at 1% into new media and incubated at 37° C.until an OD of 0.6-1.0 at 600 nm was achieved. The pathogen indicatorplates were prepared as described above. Five microliters of theBacillus culture was spot plated onto the indicator plate and incubatedfor 24 hours at 32° C. Then, plates were observed for zones ofinhibition.

As shown in Table 3 18 of the 25 Bacillus strains displayed inhibitoryactivity against the thirty-seven E. coli isolates, indicating that anactive metabolite that inhibited the pathogen was being produced. Strain3A-P4 inhibited eleven E. coli isolates, 15A-P4 inhibited fourteen E.coli isolates, and 22C-P1 inhibited eighteen E. coli isolates. Strains3A-P4, 15A-P4, and 22C-P1 were chosen for further characterization dueto their increased activity against E. coli compared to the other 25GRAS isolates. The three strains 3A-P4, 15A-P4, and 22C-P1 were testedagainst >140 pathogenic swine E. coli isolates. Each of the threeBacillus strains inhibited the >140 E. coli isolates by differingpercentages. TABLE 3 Number of E. coli Strains Inhibited by BacillusIsolates. Bacillus Isolate E. coli  3A-P4 11  3B-P5 2  3C-P2 5  6A-P1 1 6A-P2 2  6A-P5 0  6A-P6 1  6A-P8 1  6A-P12 1  7E-P1 0  9A-P1 0 10A-P4 410A-P5 0 10A-P6 2 10B-P1 2 10D-P1 3 10F-P3 1 10F-P5 2 10I-P1 4 10K-P1 214C-P1 0 14D-P1 0 15A-P4 14 15B-P3 0 22C-P1 18

B. Characterization of the E. coli Isolates:

Multiplex, RAPD, and pulse-field gel electrophoresis was performed onthe E. coli isolates obtained from diagnostic laboratories. Upon arrivalthe isolates were grown and stored as previously described.

All the E. coli isolates were genotyped by Agtech Products usingmultiplex PCR. This procedure distinguished E. coli that containedvirulence factors responsible for causing disease in swine. Purifiedgenomic DNA was isolated using a DNA isolation kit (Roche, Indianapolis,Ind.). The multiplex procedure was performed using the Amplitaq Gold DNApolymerase reagents (Roche, Branchburg, N.J.) (7). Nine oligionucleatideprimers were used in the multiplex procedure to detect the STX2e, LT,STa, and STb toxins; and the K88, K99, F18, 987p, and F41 pili. DNAfragments were separated using a 3.0% Nusieve 3:1 agarose gel(Biowhittaker, Rockland, Me.).

The pathogenic E. coli isolates were genetically analyzed using the RAPDmethod. E. coli isolates were grown in TSB overnight until an OD of 4.0at 600 nm was obtained. Purified genomic DNA was isolated using RocheMolecular Biochemicals DNA isolation kit (Indianapolis, Ind.). Once theDNA was isolated, RAPD analysis was performed using Ready-To-Go RAPDAnalysis Bead kit from Amersham Pharmacia Biotech (Piscataway, N.J.).RAPD analysis was performed using two 10-base pair oligionucleatideprimers in a polymerase chain reaction. The DNA fragments were separatedusing a 1.5% agarose gel in 0.5× TBE buffer at 100 volts.

Pulsed-field gel electrophoresis (PFGE) was performed using chromosomalDNA embedded in agarose beads and digested with Xba I via a modificationof the method of Rehberger (12). DNA fragments were separated on 0.8%agarose gel using a CHEF-DR III electrophoresis system (Bio-Rad).

DNA bands were visualized following ethidium bromide staining anddigitally captured using Syngene Genesnap darkroom software (Frederick,Md.). The determination of the molecular size of the DNA fragments anddendogram were accomplished using Bionumerics software (Kortrigjk,Belgium).

The population of E. coli isolated from infected swine herds washeterogeneous, as is shown in the Dendogram of FIG. 2. RAPD analysisdifferentiated the 48 isolates into 48 genotypic patterns. Of the 48genotypes, 12 clusters containing 2 or more isolates were identified ata coefficient of similarity of 65% or greater. The largest clustercontained 7 isolates. Eight isolates had less than 67% similarity to anyother isolate.

PFGE of intact chromosomal DNA digested with Xba 1 differentiated 42isolates into 42 genotypic patterns. Six of the 48 isolates did notproduce discernible fragments using PFGE. Of the 42 RAPD patterns, 3clusters containing 2 or more isolates were identified at a coefficientof similarity of 67% or greater. The largest cluster contained 5isolates. Thirty-six isolates had less than 67% similarity to any otherisolate.

Example 5 Characterization of Bacillus Strains 3A-P4, 15A-P4, and 22C-P1

A. DNA Fingerprinting:

DNA fingerprinting of strains 3A-P4, 15A-P4, and 22C-P1 was performed byrandom amplified polymorphic DNA (RAPD) PCR analysis on genomic DNAisolated from strains 3A-P4, 15A-P4, and 22C-P1 using Roche MolecularBiochemicals DNA isolation kit (Hoffmann-La Roche, Inc., Nutley, N.J.).RAPD PCR analysis was performed using Ready-to-go RAPD Analysis Bead kitfrom Amersham Pharmacia Biotech (Piscataway, N.J.) using two different10-base pair oligonucleotide primers in two sets of polymerase chainreactions. The two sets of DNA banding patterns, generated from twodifferent 10 bp primers, from the 3A-P4, 15A-P4, and 22C-P1 strains areshown in FIG. 3 with a Bio-Rad 100 bp molecular weight marker, in lane4, separating the sets. Although some bands were shared between thestrains, no common DNA fingerprint was found between the three strains,which indicates that 3A-P4, 15A-P4, and 22C-P1 are different strains.

B. Stability in Premix:

Strains 3A-P4, 15A-P4, and 22C-P1 were added at 5.0×10⁸ to 500 g ofswine ration premix. Premix was incubated in a 60° C. drying oven foreight weeks. Spore enumeration was performed weekly at 10⁻⁶, 10⁻⁷, and10⁻⁸.

No decrease in spore count was evident during this assay. Strains 3A-P4,15A-P4, and 22C-P1 were viable in premix rations containing primarilyminerals at temperatures that may be found in warmer climates when feedis stored in warehouses, barns, or feed bins. This assay also displayedthat these Bacillus strains are viable at a high mineral concentration.

C. Antibiotic Sensitivity:

Strains 3A-P4, 15A-P4, and 22C-P1 were grown in 50 ml of TSB overnightat 32° C. with shaking. 1.0% of each strain was inoculated individuallyinto TSA and poured into petri dishes. After the plates were solidified,the antibiotic discs were placed onto the agar surface. The plates wereincubated at 32° C. overnight. Inhibitory zones were measured inmillimeters.

The antibiotics caused minimal sized zones of inhibition against thethree Bacillus strains (Table 4). Therefore, the antibiotics should notinterfere with the growth of 3A-P4, 15A-P4, and 22C-P 1.

Further testing by broth and agar assays was performed with theantibiotic ASP-250 (chlortetracycline, sulfathiazole, and penicillincombined) against 3A-P4, 15A-P4, and 22C-P1. This antibiotic decreasedthe growth of 3A-P4, 15A-P4, and 22C-P1 by 99.9%. This antibiotic isbactericidal to the Bacillus strains. TABLE 4 Antibiotic SensitivityAssay of Strain 3A-P4, 15A-P4, and 22C-P1. Inhibitory Zones Measured inMillimeters Antibiotic Disc 3A-P4 15A-P4 22C-P1 Oxytetracycxyline 30 μg24 14 24 Tetracycline 5 μg 26 14 21 Gentamycin 10 μg 26 22 22 Neomycin 5μg 16 12 12 Penicillin 2 IU 0 11 13 Bacitracin 10 IU 8 8 8 Lincomycin 2μg 8 9 8

Example 6 Biochemical Testing of the Three Bacillus Isolates, 3A-P4,15A-P4, and 22C-P1

Strains 3A-P4, 15A-P4, and 22C-P1 were further biochemical tested usingMIDI laboratory. Ribosomal DNA analysis using Genbank showed that thesestrains were Bacillus subtilis strains. Bacillus subtilis is a speciesof Bacillus that is considered GRAS.

Example 7 Purification of Active Metabolite from Bacillus Isolates andCharacterization of Activity Against E. coli

A. Crude Purification of Active Metabolite:

To further optimize the Bacillus strains for optimal active metaboliteproduction and to further characterize the active metabolite foridentification a new assay was introduced. This assay, called the brothactivity assay, involved using the active metabolite in a crude form sofurther characterization and optimization tests could be performedwithout interference from the Bacillus cells. This assay also allows amore quantified result that is reported as percent inhibition. Anindividual colony of each Bacillus isolate was picked and inoculatedinto 50 mls of TSB and incubated at 32° C. with shaking overnight. After18 hours of incubation, 10 mls of the producer strain was harvested bycentrifugation at 5000 rpm for 10 minutes, and the supernatant wasfiltered through a 0.2 um acrodisc filter. The filtered supernatant, thecrude purified form of the active metabolite, was utilized immediatelyor stored frozen for no longer than two days before being used in anassay. From an isolated colony, E. coli pathogens were grown in TSB at37° C., with at least two 1% transfers until an OD of 0.6 at 600 nm wasreached. A test tube with TSB was inoculated with the crude form of theactive metabolite and the E. coli inoculum. A separate test tube withTSB was inoculated with only the E. coli inoculum and incubated at 37°C. Percent inhibition was determined as follows: (0% OD−sample OD)/0%OD*100. To perform this assay correctly, the amount of the crude form ofactive metabolite needed in the assay, optimal growth time, and OD forthe Bacillus isolates to produce an optimal active metabolite level, andthe incubation time of the assay was determined.

B. Active Metabolite Percentage Needed for the Broth Activity Assay:

Trials were performed to determine the optimal percentage of activemetabolite needed to inhibit E. coli in the broth assay. Bacillusisolates 3A-P4, 15A-P4, and 22C-P1 were tested against the swinepathogenic E. coli strains. E. coli isolates E.20 and E.23 were chosento be used as screening pathogens because all three preferred Bacillusisolates (3A-P4, 15A-P4, and 22C-P1) had shown inhibitory activityagainst these pathogens. From an isolated colony, pathogens were grownin TSB at 37° C., with at least two 1% transfers until an OD of 0.6 at600 nm was reached. TSB tubes were inoculated at 1% with the pathogenand 10%, 5%, 1%, 0.5%, and 0% with the crude purified form of the activemetabolite, collected as previously described, and incubated at 37° C.An OD was read at 4 and 8 hours to determine percent inhibition at eachactive metabolite percent level. Percent inhibition was determined asfollows: (0% OD−sample OD)/0% OD*100. Results are shown in Table 5. Theactive metabolite added at 10% showed the greatest inhibition of E.coli. Inhibition was also observed at the other levels. From theseresults, it was determined the active metabolite added at 10% wouldyield enough inhibition to be detected with further characterization andoptimization tests. Therefore, this percent was used in subsequentstudies. TABLE 5 Inhibition of E. coli in Broth Using DifferentPercentages of Active Metabolite Percent Percent Inhibition InhibitionInoculated E. coil E. coli Bacillus Metabolite E. 20 E. 23 IsolatePercentage 4 h 8 h 4 h 8 h 3A-P4 10 18.8 26.7 32.6 20.8 5 9.0 13.3 5.38.3 1 0 6.7 5.3 0 0.5 0 6.7 0 0 15A-P4 10 13.6 7.1 15 0 5 9.1 0 10 0 1 00 5 0 0.5 0 0 5 0 22C-P1 10 13.6 7.4 15.8 4.3 5 9.1 3.7 5.3 4.3 1 0 05.3 0

C. Active Metabolite Production Time:

Incubation time trials were performed to determine the optimal growthtime and OD for the Bacillus isolates to produce an optimal activemetabolite level. Percent inhibition against E. coli strain E.20 wasperformed and used as the indicator strain. Strains 3A-P4, 15A-P4, and22C-P1 were used.

Growth times and ODs under which the Bacillus isolates were found toproduce the most active metabolite and therefore display the greatestamount of inhibition against E. 20 were determined by sampling theculture at 12-hour intervals. At the time points, the crude purifiedform of the active metabolite was obtained as previously described andinoculated at 10% into 10 ml of TSB. Strain E. 20 was used as theindicator organism and grown as described previously. Strain E.20 wasadded at 1% to the TSB tubes containing the active metabolite. The assaywas incubated at 37° C. and OD read at 5 h and 10 h. A control tube withthe indicator organism, added at 1% to a 10 ml TSB tube, was alsoincluded in the assay to determine percent inhibition. Percentinhibition was calculated using the formula: (control OD−sampleOD)/control OD×100 for each assay time period, and the average betweenthe 5 hr and 10 hr percent inhibition was determined. Results of thisare shown in Table 6. TABLE 6 The Effect of Incubation Time of Bacillusisolates on E. coli Inhibition Producer 3A-P4 15A-P4 22C-P1 Incubation %Inhibition % Inhibition % Inhibition Time E.20 E.20 E.20 14 h 12.5 7.57.5 24 h 26.3 16.3 31.3 36 h 44.0 37.0 51.0 48 h 6.0 9.0 21.0 60 h 13.058.4 32.0 72 h 1.7 41.3 0. 84 h 0.0 26.1 4.4

For growing of the Bacillus isolates, the OD that produced an optimallevel of inhibition against E. coli strain E.20 was also determined. Thefollowing ODs were found to produce an optimal active metabolite level:3A-P4 grown to an OD of 2.5 (FIG. 4), 15A-P4 grown to an OD of 3.6 to4.15 (FIG. 5), and 22C-P1 grown to an OD of 2.04 (FIG. 6). At these ODs,the active metabolite produced by the Bacillus isolates produce the mostinhibition against E. coli. Therefore, these growth times shouldcorrelate to the highest level of active metabolite being formed.

The results obtained determined the time (Table 7) and OD at which thehighest percentage of active metabolite was formed for each of theproducing strains. This information was used to grow the producingstrains for the remainder of the characterization and optimizationtests. TABLE 7 Growth of Active Metabolite Producing Bacillus Isolates.Producer Growing 3A-P4 OD 15A-P4 OD Time in Hours (600 nm) (600 nm)22C-P1 OD(600 nm) 14 1.62 1.56 1.62 24 2.34 1.56 1.92 36 2.50 2.04 2.0448 2.22 2.28 2.1 60 2.7 3.6 2.88 72 3.06 4.14 4.2 84 4.2 3.96 4.5

D. Broth Activity Assay Incubation Time:

Incubation trials were performed to determine the time of optimal activemetabolite inhibition against E. coli using the broth activity assaymethod. Strains 3A-P4, 15A-P4, and 22C-P1 were used as producer strains,and E.20 and E.23 were used as pathogen indicator strains. The activemetabolite was obtained by growing the Bacillus strains to theirrespective ODs and obtaining the crude purified form of the activemetabolite as described previously. The crude purified form of theactive metabolite was inoculated at 10% into 10 mls of TSB. Pathogenindicator strains were grown as previously described and after reachingan OD of 0.60 (600 nm), were added at 1% to the TSB tubes containing theactive metabolite. The assay was incubated at 37° C., and an OD was readat 2, 4, 6, 21, 23, 26, 28, and 30 hours. A control tube with theindicator organism, added at 1% to a 10 ml TSB tube, was also includedin the assay to determine percent inhibition and growth pattern. Percentinhibition was calculated as previously described.

Strain 3A-P4 obtained the highest inhibition after four hours (FIG. 7)and, strains 15A-P4 and 22C-P1, after six hours (FIGS. 8 and 9). The E.coli growth curve confirmed that between four and six hours of assaytime, the E. coli was at its highest growth (FIG. 10). Thus, inhibitionby the active metabolites is not due to the E. coli decreasingnaturally.

These results determined the time of highest inhibition of pathogen bythe active metabolites. The assay times were used for all the followingcharacterization and optimization tests.

E. Further Purification of Active Metabolite:

Ammonium sulfate precipitation was performed on the active metabolitesproduced by strains 3A-P4, 15A-P4, and 22C-P1. This is a common methodfor fractioning proteins by precipitation and yields a partiallypurified protein. The partially purified proteins obtained were utilizedin further purification techniques so that a purified protein wasachieved. The purified active metabolite yields a better understandingof the microbial inhibition produced by these strains.

Ammonium sulfate concentration fractions must first be determined foreach strain to ascertain the amount of ammonium sulfate to add toprecipitate the active metabolite. Strains 3A-P4, 15A-P4, and 22C-P1were grown separately in TSB to their respective OD. Cell freesupernatants were obtained by centrifugation at 6000×g for 20 minutes at4° C. Ammonium sulfate was added to the supernatant in 10% incrementsuntil a concentration of 70% is obtained. After the addition of one ofthe ammonium sulfate concentrations, the supernatant was kept at 4° C.for 2-24 h. The supernatant was harvested by centrifugation at 6000×gfor 20 minutes. The supernatant (10 ml) was placed in an Amicon 10,000MWC centrifugal device and centrifuged at 2000×g until one ml was leftin filter. This fraction was then filtered through a 0.2 um filter andtested for activity against E. coli using the spot plate method. Thepellet obtained from the above centrifugation process was resuspendedwith 10 ml of Tris-HCl and dialyzed overnight with stirring against 2liters of the same buffer using a Spectra/Por no. 3 dialysis tubing. Itshould be noted that instead of dialysis, the pellet sample can also beplaced in an Amicon filter and centrifuged at 2000×g until no liquidremains in the filter. Tris-HCl (0.05M)(10 ml) is added to the filterapparatus and centrifuged at 2000×g until no liquid remains in filter.This step is repeated and the filter is centrifuged at 2000×g until oneml is left in filter. The preparation was then filtered through a 0.2 umfilter and tested for activity against E. coli using the spot platemethod. Ammonium sulfate was added to the remainder of the supernatantand the precipitation procedure repeated until the concentration ofammonium sulfate reached 70%.

The ammonium sulfate concentration that precipitates the activemetabolite into the pellet after centrifugation is the ammonium sulfatepercentage used to partially purify the active metabolite from eachstrain. Ammonium sulfate concentration needed to precipitate the activemetabolite of 15A-P4 is 30%. To decrease unwanted protein and obtain amore partially purified protein it is best to add ammonium sulfate firstto the sample at a lower concentration, such as 10%. This precipitatesthe unwanted protein, leaving the active metabolite in solution. The 30%ammonium sulfate can then be added to precipitate the active metabolite.The supernatant is then collected by centrifugation, as previouslydescribed, and the ammonium sulfate concentration needed to precipitatethe active metabolite is added.

F. Characterization of the Purified Active Metabolite Produced by 15A-P4by Gel Electrophoresis:

Strain 15A-P4 was grown to its optimal OD as previously described. Thecrude form of the active metabolite was obtained as previouslydescribed. The active metabolite was then partially purified, after 0.1mM PMSF and 1.0 M DTT were added to increase protein stability, byperforming a 10% and 30% ammonium sulfate precipitation as previouslydescribed. The pellet and supernatant fractions from both percentageprecipitations were kept and spot plated onto an E. coli indicator plateas previously described.

The ammonium sulfate fractions were examined using polyacrylamide gelelectrophoresis (PAGE) in the presence of 0.1% sodium dodecyl sulfate(SDS) in a Mini-Protean 3 Cell (Bio-Rad, Hercules, Calif.). The sampleswere prepared following the protocol provided with the SDS-PAGEmolecular weight standards kit (Bio-Rad). A precast 10% polyacrylamideTris HCl Ready Gel (Bio-Rad) was used. The current was run at 10 mAconstant current until the bromphenol blue entered the separating gel.Then the current was increased to 15 mA. The gel was stained usingGelCode® Blue stain reagent (Pierce, available from Fisher Scientific,Hampton, N.H.) according to the manufacture's directions. A broad rangeand low range standard (Bio-Rad) was used that included the followingproteins and molecular weights: Myosin (200,000), β-galactosidase(116,250), Phosphorylase b (97,400), Serum albumin (66,200), Ovalbumin(45,000), Carbonic anhydrase (31,000), Trypsin inhibitor (21,500),Lysozyme (14,400), and Aprotinin (6,500). The 10% pellet fraction andthe 30% supernatant fraction did not inhibit E. coli during the spotinhibition assay. The 10% supernatant and 30% pellet did inhibit E. coliduring the spot inhibition assay. The pellet and supernatant fractionsyielded a band with a molecular weight range between 31,000 and 45,000.Therefore, this band is believed to be the inhibitory protein. (FIG. 11)

G. Characterization of the Active Metabolite Produced by 15A-P4 UsingLow Pressure Column Chromatography:

After ammonium sulfate precipitation, the active metabolite in the 30%pellet fraction was applied to different chemistry columns to determineprotein characteristics. The Bio-Rad High Q anion exchange 1 mlcartridge and the Bio-Rad HIC hydrophobic/hydrophilic 1 ml cartridgewere explored. To determine characteristics of the protein, 0.5 ml ofthe active metabolite, after ammonium sulfate precipitation wasperformed, was mixed with the elution buffer, and was placed on thecolumn. A high salt buffer and low salt buffer were applied to thecolumn to determine under what conditions the active metabolite wouldadhere to the column. Tris HCl 50 mM with 10 mM NaCl was used as thehigh salt buffer for the High Q column and Tris HCl 50 mM with 1.0 mMNaCl added was used as low salt buffer for the High Q column. 100 mMsodium phosphate with no salt added was used as the low salt buffer forthe HIC column and 100 mM sodium phosphate with 2.4M ammonium sulfateadded was used as the high salt buffer for the HIC column. A flow rateof 0.7ml/min for 25 minutes was used with each buffer. Two largefractions were collected first, one fraction was what came off thecolumn after running a high salt buffer through the column and the otherfraction was collected after a buffer containing no salt was ran throughthe column. These fractions were then concentrated using the Amiconcentrifugal device by placing the fractions in a 10,000 MWC Amiconcentrifugal device and spun at 3000 rpm until dry. Two buffer washeswere performed, and the protein was reconstituted to 300 μl.

With the HIC column, the fraction collected during the high salt bufferapplication yielded a positive inhibition with the spot plate assay. Theseparation principle behind the HIC column is not yet fully understood.All theories support that interaction is related to the hydrophobicsurface area found on all proteins and that it is increased by highionic strength and high temperature (11). Therefore, the fact that theprotein eluted with a high concentration of salt leads to suspect thatthe protein is hydrophilic in nature.

With the High Q anion exchange column, both the high salt bufferfraction and the no salt buffer fraction yielded no inhibition on thespot plate assay. The procedure was repeated and nine fractions werecollected after a high salt buffer was applied and nine fractions werecollected after a no salt buffer was applied. Three of the fractionscollected with the salt buffer showed inhibition on the spot plateassay. These three fractions also had 60→100 mg/dl of protein using theprotein determination test. None of the fractions from the no saltbuffer showed inhibition, but two fractions had 20-30 mg/dl of protein.Therefore, the fact that the protein eluted from an anion column with ahigh concentration of salt demonstrates that the protein is a cation.

In summary, it was discovered that the active metabolite produced bystrain 15A-P4 has a molecular weight between 31,000 and 45,000, is acation, and appears to be hydrophilic.

Example 10 Determination of Stability of the Active Metabolites Producedby 3A-P4, 15A-P4, and 22C-P1

The stability of the active metabolite of the Bacillus isolates wasassessed. This information also helps to characterize the activemetabolites. Assays were performed using the crude form of the activemetabolite to determine enzyme degradation, heat stability, and mode ofaction. The activity of the active metabolite was determined afterexposure to enzymes and heat.

A. Enzyme Degradation Assay:

Enzyme degradation trials were performed on strains 3A-P4, 15A-P4, and22C-P1 to determine if the active metabolite formed was a protein.Producers were grown in TSB as previously described, and the activemetabolite was obtained in the crude purified form.

Enzymes (all obtained from Sigma, St. Louis, Mo.) used were: {acute over(α)}-chymotrypsin, pronase E, proteinase K, pepsin, trypsin, andcatalase. Two hundred and fifty milligrams of each enzyme was added to100 ml of sterile cold distilled water and kept on ice before use. 1 mlof each enzyme was separately added to 4 mls of the crude purifiedactive metabolite for a final concentration of 500 μg/ml. Afterincubated at 37° C. for 60 minutes, each sample was assayed forbacteriocin activity using the broth activity assay method. Sampleswithout enzymes were used as controls.

The enzyme treated active metabolite was added to a 10 ml TSB tube at10%. Strain E.23 was used as the indicator organism and was grown aspreviously described. The indicator was then added to the TSB tubes,which contained the active metabolite, at a 1% concentration. Sampleswithout enzyme-treated active metabolites and samples without activemetabolites were used as controls. Percent inhibition was determined aspreviously described.

The active metabolite produced by strain 3A-P4 was found to be sensitiveto {acute over (α)}-chymotrypsin, pepsin, catalase, and pronase E butnot affected by trypsin or proteinase K. Active metabolite produced bystrain 15A-P4 was found to be sensitive to catalase and pronase E butnot affected by {acute over (α)}-chymotrypsin, pepsin, trypsin, orproteinase K. The active metabolite produced by strain 22C-P1 was foundto be sensitive to trypsin and pronase E but not affected by {acute over(α)}-chymotrypsin, pepsin, catalase, or proteinase K.

B. Heat Assay:

The temperature sensitivity of the crude purified active metabolitesproduced by strains 3A-P4, 15A-P4, and 22C-P1 were examined. Theisolates were grown as previously indicated and the crude activemetabolite was obtained. The active metabolites were heated to 100° C.for 1, 5, 10, and 15 minutes; cooled to room temperature; and inoculatedat 10% into 10 ml of TSB. The active metabolites were also autoclavedfor 20 minutes at 121° C. and assayed for inhibitory activity. StrainE.23 was used as the indicator organism and was grown as previouslydescribed and inoculated at 1% into the 10 ml of TSB containing theactive metabolite. The assay was incubated at 37° C. and OD read ateither four or six hours. Percent inhibition was calculated aspreviously described.

All three of the active metabolites' activity was reduced after heattreatment (Table 8). But all three active metabolites still had someinhibitory activity after heat treatment. TABLE 8 Percent inhibition of3A-P4, 15A-P4, and 22C-P1 after heat treatments. 3A-P4 15A-P4 22C-P1 %Inhibition % Inhibition % Inhibition Heat Treated No Heat Heat TreatedNo Heat Heat Treated No Heat  1 Min 100° C. 100 100 94.4 100 88.3 100  5Min. 100° C. 75 100 87.6 100 56.3 100 10 Min. 100° C. 50 100 75.3 10046.2 100 15 Min. 100° C. 50 100 62.0 100 25.7 100 Autoclaved 32.4 10036.7 100 20.5 100

C. Mode of Action:

Tests were performed to determine if the active metabolites produced bystrains 3A-P4, 15A-P4, and 22C-P1 were bactericidal or bacteriostatic toE. coli. Strains 3A-P4, 15A-P4, and 22C-P1 were grown to their optimalOD as previously described. The crude form of the active metabolite wasobtained as previously described. E. coli strains E.20 and E.23 weregrown as previously described.

The active metabolite of each strain was tested separately and added at10% to a 10 ml TSB tube. Strains E.20 and E.23 were added separately at1% to the TSB tube containing the active metabolite. A TSB tubeinoculated with only E.20 or E.23 at 1% was used as the control. Thetubes were incubated at 37° C., and an OD (600 nm) was obtained everytwo hours for a total of eight hours. Time zero values were alsoobtained. To obtain live E. coli counts from the inoculated TSB tubesplating was performed. Serial dilutions were made every two hours for atotal of eight hours and plated on TSA and incubated at 37° C.overnight. Time zero values were also obtained. The plates were countedafter 24 h of incubation.

Strain 3A-P4 active metabolite decreased E. coli counts for both E. colistrain E.20 (FIG. 12A) and strain E.23 (FIG. 12B) by one log anddecreased the OD values. Strain 15A-P4 active metabolite decreased E.coli counts for both E. coli strain E.20 (FIG. 13A) and strain E.23(FIG. 13B) by three to four logs and also decreased the OD values.Strain 22C-P1 active metabolite decreased E. coli counts for both E.coli strain E.20 (FIG. 14A) and strain E.23 (FIG. 14B) by half a log toone log and also decreased the OD values. The results indicate that15A-P4 active metabolite is bactericidal, and 3A-P4 and 22C-P1 activemetabolites are at least bacteriostatic. Strains 3A-P4 and 22C-P1 activemetabolites may also prove to be bactericidal if the assay was allowedto continue longer.

Example 11

A. Media Optimization:

Strains 3A-P4, 15A-P4, and 22C-P1 were grown in different media todetermine a media that would yield the highest cell and spore growth.The protein found in TSB was substituted at different percentage levelswith other proteins. Carbohydrates and minerals, common to industry,were also included in the different media at different percentagelevels.

Strains 3A-P4, 15A-P4, and 22C-P1 were inoculated into the abovedifferent media and grown at 32° C. with shaking. Samples for sporeyield were aseptically removed at 24 and 48 h. The sample was placed ina 63° C. water bath for 35 minutes to kill all vegetative cells. Sporeswere enumerated by plating serial dilutions on TSA, which were incubatedfor 24 hours at 32° C. Cells were enumerated by plating serial dilutionson TSA of the culture at 24 h and 48 h, which were also incubated for 24at 32° C. The media that yielded the highest cell and spore growth foreach strain is listed below.

B. Media Yielding Highest Cell and Spore Growth:

For 3A-P4, growth media was Primagen 2%, Sucrose 5 g/L, Dipotassiumphosphate 2.5 g/L, 0.5 g/L, MgSO₄7H₂O, 0.12 g/L, FeSO₄7H₂O, 0.05 g/L,MnSO₄H₂O, 0.004 g/L, Zn SO₄7H₂O, and 0.05 g/L CaCl. Growth conditionswere: 32° C. with shaking for 48 hours to obtain a spore count of atleast 1×10⁹.

For 15A-P4, growth media was peptonized milk protein 5%, Dextrose 2.5g/L, Dipotassium phosphate 2.5 g/L, 0.5 g/L MgSO₄7H₂O, 0.12 g/L FeSO₄7H₂O, 0.05 g/L MnSO₄ H₂O, 0.004 g/L Zn SO₄ 7H₂O, and 0.05 g/L CaCl.Growth conditions were 32° C. with shaking for 48 hours to obtain aspore count of at least 1×10⁹.

For 22C-P1, growth media was Primagen, 2%, Dextrose 2.5 g/L, Dipotassiumphosphate 2.5 g/L, 0.5 g/L MgSO₄ 7H₂O, 0.12 g/L FeSO₄ 7H₂O, 0.05 g/LMnSO₄ H₂O, 0.004 g/L Zn SO₄ 7H₂O, and 0.05 g/L CaCl. Growth conditionswere 32° C. with shaking for 48 hours to obtain a spore count of atleast 1×10⁹. Primagen and peptonized milk protein obtained from QuestInternational, Hoffman Estates, Ill.

Example 12

Field Trial A:

The objective of Field Trial A was to evaluate the ability of theselected Bacillus strains to reduce the incidence of E. coli disease andto improve performance in the nursery phase.

The site is located approximately 7 miles east of Pipestone, Minn. Itwas a farrow to finish farm with an E. coli mortality of 20% withoutvaccine and antibiotic use. The intervention of vaccines and antibioticshad decreased the E. coli mortality to 5-10%.

The farm consisted of one nursery barn with two rooms. Each room had tworows of six pens with each pen holding 25 pigs. Each room had a capacityof holding 300 pigs. Pigs remained in the nursery on an average of 28days before being moved to the finishing facility.

The pigs were weaned at 26 days of age and were sorted by sex andassigned to one of three weight classes (light, medium and heavy).Control and treated pigs were placed in separate rows to decrease thepossibility of cross over contamination between treated and control pigsof the Bacillus strains fed to the treated pigs. Each row had three pensof gilts and three pens of barrows with one light, one medium, and oneheavy weight group in each sex.

The E. coli vaccine was given to all weaned pigs. Several injectableantibiotics (gentamicin, enrofloxacin) were given to both control andtreated pigs when scouring was observed.

The treated pigs received Product 1 in a basemix form, containingBacillus strains and carriers as follows: 30% 3A-P4, 60% 15A-P4, 10%22C-P1 at a final product count of 3.0×10⁷ cfu/g and 40% rice hulls, 19%dried brewers grain, 40% limestone, and 1% baylith. The basemix was thenadded to the standard farm pellet diet and grind and mix diet at therate of 5 lbs/ton of feed to make the final Bacillus inclusion rate7.35×10⁴ cfu/g. The pellet diet was started on day one post-weaning, andProduct 1 was continued in all diet phases until the end of the nurserystage. The control pigs received the same pelleted and grind and mixdiets as the treated pigs except they were devoid of the Bacillusstrains.

Included in the nursery pellet diet for control and treated pigs was theantibiotic ASP-250. All the grind and mix rations for both control andtreated pigs included BMD and 3-Nitro. Normal protocol was utilized forpig management.

Mortality and disease incidence was recorded weekly in both the treatedand control pigs. Pen weight, pen sex, and number of pigs in pen wererecorded on day one and day 28 of the field trial.

Before the field trial began environmental, rectal, and fecal swabs wereobtained from the nursery. E. coli strains from the swabs were grown andisolated at Agtech Products and kept frozen for future use. MultiplexPCR was used to determine if a strain was pathogenic.

All pathogenic E. coli isolates were individually tested in vitroagainst the three Bacillus strains included in Product 1. This was doneusing broth activity assay. Each active metabolite produced by theBacillus in Product 1 was tested against each pathogenic E. coli strainfound on the farm using the broth activity assay to obtain percentdegree of inhibition. The degree of inhibition was monitored by way ofoptical density readings using a spectrophotometer. Results of thedegree of inhibition are shown below in Table 12.

Feeding Product 1 to nursery pigs during Field Trial A decreasedmortality. Mortality in the control pigs remained high at 7.0%, however,mortality in the pigs fed Product 1 decreased to 1.4%. Pigs had typicalsymptoms of E. coli disease, as seen previously and diagnosed on thisfarm. Therefore, the cause of mortality was determined to be attributedto E. coli disease. No improvement in performance was seen during thistrial. Treated pigs gained an average of 17.45 lbs per pig, and controlpigs gained an average of 18.98 lbs per pig (Tables 9 and 10). TABLE 9Effect of Product 1 during Field Trial A. Treated Control Group GroupPig Number In 139 143 PigNumber Dead 2 10 Percent Mortality 1.4 7.0

TABLE 10 Results of Feed Trial A. Pen Treated Gilt or Weaning Date PenDate Pen # Weight No. Or Barrow age in Pig # Weight Out Pig # Weightdead Gained/pig 1 T B 26-28 May 21, 2002 23 584 Jun. 18, 2002 23 109622.3 2 T B 26-28 May 21, 2002 24 479 Jun. 18, 2002 24 877 16.6 3 T B26-28 May 21, 2002 24 425 Jun. 18, 2002 23 816 1 17.8 4 T G 26-28 May21, 2002 23 394 Jun. 18, 2002 23 729 14.6 5 T G 26-28 May 21, 2002 22326 Jun. 18, 2002 22 729 18.3 6 T G 26-28 May 21, 2002 23 256 Jun. 18,2002 22 573 1 14.9 7 C B 26-28 May 21, 2002 24 290 Jun. 18, 2002 24 57411.8 8 C B 26-28 May 21, 2002 24 372 Jun. 18, 2002 23 803 1 19.4 9 C B26-28 May 21, 2002 25 425 Jun. 18, 2002 24 869 1 19.2 10 C G 26-28 May21, 2002 23 404 Jun. 18, 2002 22 805 1 19.0 11 C G 26-28 May 21, 2002 24497 Jun. 18, 2002 22 902 2 20.3 12 C G 26-28 May 21, 2002 23 540 Jun.18, 2002 18 859 5 24.2

One hundred swabs were collected from the nursery. From the 100 swabs,100 E. coli isolates were tested to determine their pathogenicity usingthe multiplex PCR procedure. Fifty-three of the 100 isolates were foundto contain one or more genes associated with pathogenicity. Thegenotypes and the results of the inhibition of the E. coli isolates bythe Bacillus in Product 1 are shown below in Table 11. All the E. coliisolates were inhibited by all three Bacillus strains ranging from 18.2to 96% inhibition of growth. Strain 15A-P4 demonstrated the mosteffective inhibition against pathogenic E. coli isolated from FieldTrial A. TABLE 11 Characterization of pathogenic E. coli isolates fromField Trial A. E. coli Source of Bacillus Strain Bacillus StrainBacillus Strain Sample sample Multiplex Results 3AP4 15A-P4 22C-P1 E.271 Fecal STb 60.0 91.5 55.0 E. 273 Fecal STa 45.2 82.7 64.0 E. 274Fecal STb 44.2 84.2 60.0 E. 276 Fecal K88 46.2 95.0 52.0 E. 278 FecalF18. STX2e. 41.7 87.1 35.0 STa. STb E. 279 Fecal F18. STX2e. 36.8 86.537.5 STa. STb E. 284 Fecal STb 44.0 85.8 53.8 E. 285 Fecal K88 38.0 86.451.9 E. 294 Fecal F18. STX2e. 42.1 92.8 22.5 STa. STb E. 311 Fecal STb42.0 86.7 51.9 E. 315 Fecal STb 39.6 86.9 47.9 E. 317 Fecal STb 48.078.8 53.6 E. 318 Fecal K88 50.0 88.8 50.0 E. 319 Fecal F18. STX2e. 36.188.8 36.8 STa. STb E. 320 Fecal K88 45.8 88.8 50.0 E. 323 Fecal STb 47.990.8 57.4 E. 324 Rectal K88 58.3 96.8 55.8 E. 325 Rectal STb 51.9 88.861.4 E. 327 Rectal K99. STa 65.0 92.7 31.8 E. 328 Rectal K99. STa 55.090.4 38.5 E. 329 Rectal K99. STa 59.1 90.9 41.7 E. 337 Rectal F18.STX2e. 41.2 90.0 23.7 STa. STb E. 361 Rectal F18. STX2e. 36.8 92.4 25.0STa. STb E. 374 Environment F18. STX2e. 47.4 91.9 25.0 STa. STb E. 378Environment F18. STX2e. 37.5 89.5 18.2 STa. STb E. 379 Environment F18,STX2e, 31.8 87.3 21.7 STa, STb

In Field Trial A, feeding Product 1 to nursery swine throughout thenursery period decreased mortality due to E. coli disease. Product I didnot enhance nursery swine performance in Field Trial A. The fact thatperformance was not enhanced in this trial may be due to the fact thatin our laboratory testing we confirmed that ASP-250, which was includedin the nursery pellet diet for control and treated pigs, is bactericidalto the Bacillus strains included in Product 1. This is most likely dueto the sulfamethazine portion of this antibiotic. Penicillin andaureomycin (chlortetracycline) have been shown in laboratory testing notto have little effect on the Bacillus strains in Product 1.

Example 13

Field Trial B-1 and B-2:

The objective of Field Trial B-1 and B-2 was to develop a feed additiveproduct containing biologically-active active metabolites from Bacilluscapable of enhancing the performance of swine by reducing intestinalpathogens such as E. coli.

The site for Field Trial B-1 and B-2 was a farrow to finish facilitylocated approximately 7 miles east of Pipestone, Minn. (Same site usedin Example 12). A new nursery to finish facility was built in the springof 2003. Field Trials B-1 and B-2 were performed in this new facility.No E. coli disease was evident in the new facility.

The new facility consisted of four rooms with two large pens in eachroom capable of housing pigs from the nursery phase through thefinishing phase. For our trials, the pens in each room were divided downthe middle to make four smaller pens. Each pen could hold on the average70 pigs.

The pigs were weaned at 18-21 days of age and were sorted by sex to oneof the treatment groups. The control and treated group was comprised ofone pen of barrows and one pen of gilts. The pigs remained in the studyfor 28 days.

The treated pigs received Product 2 in a basemix form containingBacillus strains and carriers as follows: 100% 22C-P1 at a final productcount of 3.0×10⁸cffu/g and 40% rice hulls, 19% distilled brewers grain,40% limestone, and 1% baylith. The basemix was then added to thestandard farm pellet diet and grind and mix diet at the rate of 5lbs/ton of feed to make the final Bacillus inclusion rate 7.35×10⁵ CFU/gof feed. The pellet diet was started on day one post-weaning, andProduct 2 was continued in all diet phases until the end of the nurserystage. The control pigs received the same pelleted and grind and mixdiets as the treated pigs except they were devoid of the Bacillusstrain.

The pellet diet was devoid of antibiotics. And all the grind and mixrations for both control and treated pigs included BMD, 3-Nitro, andCTC. Normal protocol was utilized for pig management.

Mortality and disease incidence was recorded weekly in both the treatedand control pigs. Pen weight, pen sex, and number of pigs in pen wererecorded on day one and day 33 (Field Trial B-1) and day 31 (Field TrialB-2) of the field trial.

Feeding Product 2 to nursery pigs during Field Trials B-1 and B-2increased performance. In Field Trial B-1 weight gained per pig andaverage daily gain (ADG) was 11.3% higher in pigs fed Product 2. InField Trial B-2 weight gained per pig was 3.9% higher in pigs fedProduct 2, and ADG was 4.0% higher in pigs fed Product 2. The overalleffect is summarized in Table 12. E. coli disease did not occur duringthese trials; therefore mortality due to E. coli was not analyzed. TABLE12 Overall effect of Product 2 for Field Trials B-1 and B-2. TreatedControl % Group Group Difference Weight gained/ 23.48 21.8 7.71 pig ADG0.737 0.683 7.91

In Field Trials B-1 and B-2, feeding Product 2 to nursery swinethroughout the nursery period increased ADG by 7.9% and weight gainedper pig by 7.7%. Product 2 was effective at enhancing nursery swineperformance in Field Trials B-1 and B-2.

Example 14

Field Trial C

The objective of Field Trial C was to evaluate the ability of theselected Bacillus strains to reduce the incidence of E. coli disease andto improve performance in the nursery phase.

The field trial site is located approximately 7 miles east of Pipestone,Minn. It was a nursery and finish farm with an E. coli mortality of 15%without vaccine and antibiotic use. The intervention of vaccines andantibiotics had decreased the E. coli mortality to 3-5%.

The farm consisted of two nursery barns with two rooms in each barn.Each room had four rows of six pens with each pen holding 25 pigs. Eachroom had a capacity of holding 600 pigs. Pigs remained in the nurseryfor 7-8 weeks before being moved to the finishing facility.

Pigs were placed in the nursery at 16-18 days of age upon arriving atthe farm and were sorted by sex and assigned to one of two weight groups(light and heavy pigs). Control pigs were placed in one room and treatedpigs in the other room to minimize the chance for Bacillus crosscontamination. The E. coli vaccine was given to control pigs only.

The treated pigs received Product 1 described in Example 12 in both thestandard farm pellet diet and in the grind and mix diet at 7.35×10⁴cfu/g inclusion rate. The pellet diet was started upon placement, andProduct 1 was continued in all diet phases until the end of the nurserystage. The control pigs received the same pelleted and grind and mixdiets as the treated pigs except they were devoid of the Bacillusstrains. None of the diets included antibiotics aimed at treating E.coli disease. Normal protocol was utilized for pig management.

Mortality and disease incidence was recorded weekly in both the treatedand control pigs. Room weight was recorded upon placement of pigs and atthe end of the field trial.

Before the field trial began environmental, rectal, and fecal swabs wereobtained from the nursery. Strains from the swabs were grown andisolated at Agtech Products and kept frozen for future use. MultiplexPCR was used to determine if a strain was pathogenic.

All pathogenic E. coli isolates were individually tested in vitroagainst the three Bacillus strains included in Product 1. This was doneusing broth activity assay. Each active metabolite produced by theBacillus in Product 1 was was tested against each pathogenic E. colistrain found on the farm using the broth activity assay to obtainpercent degree of inhibition. The degree of inhibition was monitored byway of optical density readings using a spectrophotometer.

Twenty days into the field trial challenges from pathogenic E. coliresulted in a death loss of 0.50%-0.75% in the pigs fed Product 1compared to a death loss of 3.0%-5.0% for pigs fed the control diet (noProduct 1). Shortly after this period a S. suis infection became a majorchallenge at this farm and subsequent deaths were diagnosed at necropsyas S. suis.

One hundred swabs were collected from the nursery. From the 100 swabs,100 E. coli isolates were tested using multiplex PCR procedure toidentify pathogenic strains. Thirty-one of the 100 isolates were foundto be pathogenic. Genotypes for each of the 31 isolates and the resultsof the inhibition of the E. coli by the Bacillus in Product 1 are shownin Table 13. All the E. coli isolates were inhibited by all threeBacillus strains ranging from 6.9 to 96% inhibition of growth. Strain15A-P4 demonstrated the most effective inhibition against pathogenic E.coli isolated from Field Trial C. TABLE 13 Characterization of thepathogenic E. coli isolates from Field Trial C. Bacillus Strain BacillusStrain Bacillus Strain E. coli Sample Multiplex Results 3A-P4 15A-P422C-P1 E. 54 Rectal F18 83.5 98.5 19.2 E. 55 Rectal K88 80.7 95.7 14.3E. 57 Rectal STb 97.7 99.2 52.1 E. 66 Fecal K88 69.0 91.0 19.2 E. 67Fecal K88 58.6 96.3 16.7 E. 69 Fecal K88 60.0 80.5 NA E. 74 EnvironmentK88 53.8 95.5  6.9 E. 86 Rectal F18 91.0 95.8 NA E. 87 Fecal STa, STb,66.0 NA NA K88, STx2e E. 90 Fecal F18 64.6 97.9 20.7 E. 91 Fecal F1875.4 97.9 15.5 E. 96 Fecal K88 79.2 89.1 NA E. 104 Rectal STb 92.2 95.237.0 E. 106 Rectal F18 89.5 96.4 NA E. 110 Fecal Sta 79.1 79.2 NA E. 115Fecal STa, STb, 58.9 85.3 15.0 F18, STx2e E. 116 Fecal STa, STb, 50.085.0 22.0 F18, STx2e E. 117 Fecal STb 57.7 93.0 16.7 E. 118 Fecal K8865.4 95.8 16.7 E. 123 Environment STa, STb, 37.0 63.1 24.0 F18, STx2e E.239 Environment K88 93.9 95.8 15.0 E. 240 Fecal Sta 56.5 99.0 33.0 E.241 Rectal F18, STx2e, 83.3 98.2 NA STb E. 246 Fecal K88 53.8 94.2 35.7E. 247 Fecal Sta 33.3 98.9 28.6 E. 251 Fecal K88, STa 39.3 90.7 23.5 E.252 Fecal F18 97.7 99.2 30.0 E. 256 Rectal K88 59.2 92.8 30.0 decreasedE. 257 Environment K88, STx2e, 66.3 98.5 28.6 STb E. 265 Fecal K88 81.496.7 12.5 E. 268 Fecal F18 96.3 99.2 25.0

In Field Trial C, feeding Product 1 to nursery swine throughout thenursery period mortality due to E. coli disease. During Field Trial C,Product 1 did not enhance nursery swine performance. The lack of animprovement in performance may have been due to disease issues caused byother microorganisms, such as S. suis, and management issues.

Example 15

Field Trial D:

The objective of Field Trial D was to evaluate the ability of theselected Bacillus strains to reduce the incidence of E. coli disease inthe nursery phase. The site is located in Indiana. It is a 2000 sowfarrow to finish farm. E. coli had been diagnosed previously by theveterinarian.

The farm has multiple nurseries. The study was performed at the WendellCates nursery. The rooms consisted of two rows of 12 pens withapproximately 20 pigs per pen. Pigs remained in the nursery on anaverage of 35 days before being moved to the finishing facility.

The pigs came into the nursery between 11 and 13 pounds and were sortedby weight into three groups—light, medium, and heavy. Control pigs (403head) were placed in one room and treated pigs (440 head) in anotherroom to minimize the chance for Bacillus cross contamination.

Treated and control pigs received penicillin in the water for coughing.The control pigs received gentamycin in the water for scours.

The treated pigs received Product 3 in a basemix form containingBacillus strains and carriers as follows: 10% of the total count ofstrain 15A-P4, 90% of the total count of strain 22C-P1 at a finalproduct count of 3.0×10⁸ cfu/g and 40% rice hulls, 19% dried brewersgrain, 40% limestone, and 1% baylith. The basemix was then added to thestandard farm pellet diet and grind and mix diet at the rate of 5lbs/ton of feed to make the final Bacillus inclusion rate 7.35×10⁵ cfu/gof feed. Product 3 was added to both the standard farm pellet diet andin the grind and mix diet at 7.35×10⁵ CFU/g inclusion rate. The pelletdiet was started on day one post-weaning, and Product 3 was continued inall diet phases until the end of the nursery stage. The control pigsreceived the same pelleted and grind and mix diets as the treated pigsexcept they were devoid of the Bacillus strains. Normal protocol wasutilized for pig management.

Mortality and disease incidence, and pig numbers going into the trialand into the finisher were recorded.

Rectal and fecal swabs were obtained from the nursery during an E. colioutbreak. Three swabs were from treated pigs and three swabs came fromcontrol pigs. E. coli strains were grown and isolated at Agtech Productsand kept frozen for future use. Multiplex PCR was used to determine if astrain was pathogenic.

Treated pigs had a total death loss of 4.1%. Death loss due to E. colidisease/scours was 1.4%. Control pigs had a total death loss of 12.2%.Death loss due to E. coli disease/scours was 9.4%. Treated pigs had aplacement rate of 94.5% of animals into the finisher phase compared tocontrol pigs which had a finisher placement of 87.9% (Table 14).

Three swabs were sent from treated pigs and three swabs were sent fromcontrol pigs. From the six swabs, 18 E. coli isolates were tested todetermine their pathogenicity using the multiplex PCR procedure. Thenine isolates that came from the three swabs obtained from the treatedpigs were negative for pathogenic E. coli. Four of the nine isolatesthat came from the three swabs obtained from the control pigs werepositive for the K88 pili gene and the Lt and Stb enterotoxin gene, asshown in Table 15. Therefore, the isolates from the control pigs werepathogenic E. coli and represented two of the three swabs taken fromcontrol pigs. TABLE 14 Death causes during Field Trial D. Numbersrepresent the number of pigs that died due to that cause. Treated PigsControl Pigs (received Product 3) (did not receive Product 3) Scour 6 38Small 1 1 Very Small 3 10 Fighting 1 0 Flu/Respiratory 2 0 Not Eating 10 Gaunt 1 0 Not Sure 3 0 Total Death Loss 18 49 Total E. coli/Scour 6 38Loss

TABLE 15 Characterization of E. coli isolates obtained from Field TrialD. Multiplex Results on isolates Swab Treated or Control Pigs obtainedfrom swab 1 Treated Negative for E. coli virulence factors 2 TreatedNegative for E. coli virulence factors 3 Treated Negative for E. colivirulence factors 4 Control Negative for E. coli virulence factors 5Control K88, LT, Stb 6 Control K88, LT, Stb

In Field Trial D, feeding Product 3 to nursery swine throughout thenursery period decreased mortality due to E. coli disease and increasedthe number of pigs placed in finisher.

Example 16

Field Trial E:

The objective of Field Trial E was to evaluate the ability of theselected Bacillus strains to reduce the incidence of E. coli disease andto improve performance in the nursery phase.

The study site is located approximately 7 miles east of Pipestone, Minn.The cooperating producer's facility consists of approximately 450-500sows of Babcock genetics and is a farrow to finish operation. Giltstypically enter farrowing at approximately 11 months of age and aretaken through 5 farrowings. E. coli (F18) has been diagnosed on the farmwith outbreaks occurring recently.

The nursery facility consists of six rooms with each room divided intoone row of six pens. Each pen typically houses 25-35 pigs and pigsremain in the nursery on an average of 30 days before being moved to thefinishing facility.

The pigs were weaned at 15 days of age and were sorted into one of threeweight classes (light, medium, and heavy). Gilts and barrows werecommingled within the same weight group in each of the pens. Ideally,the same weight group between the treated and control pens did notdiffer by more than 0.5 lbs.

A barrier was placed in between the two middle pens to divide the rowinto three pens of control and three pens of treated pigs. This barrieralso minimized cross contamination between treated and control pigs.

The treated pigs received Product 3 as described in Example 15 in boththe standard farm pellet diet and in the grind and mix diet at 7.35×10⁵cfu/g inclusion rate. The pellet diet was started on day onepost-weaning, and Product 3 was continued in all diet phases until theend of the nursery stage. The control pigs received the same pelletedand grind and mix diets as the treated pigs except they were devoid ofthe Product 3 Bacillus strains. The control diet did contain anothercommercial Bacillus product in the pelleted rations and the first grindand mix ration. Egg immunoglobins were also included in the controlpelleted rations.

Included in the nursery pellet diet for control and treated pigs was theantibiotic T135C400 (Denagard and chlortetracycline). Normal protocolwas utilized for pig management.

Mortality and other clinical signs of disease were recorded in both thetreated and control pens. Comments on cause of death were also recorded.Pigs were weighed by pen using the Transcell Technology TI-500SS B.Weights were collected at weaning (day 0), day 7, and day 28. The amountof feed fed was recorded daily, and on the last day of trial all theleft over feed was weighed.

Rectal and fecal swabs were obtained from the nursery during an E. colioutbreak. E. coli strains were grown and isolated at Agtech Products andkept frozen for future use. Multiplex PCR was used to determine if astrain was pathogenic.

Data were analyzed using the PROC MIXED procedure of the SAS computerprogram, and the effects of block and treatment, with day included, totake into account repeated measures and interactions, were evaluated.Data is summarized in Table 16.

Referring to FIGS. 15A and 15B, pig weight was influenced by treatment(P<0.01), block (P<0.0001) and treatment×block (P<0.01) and block×day(P<0.01). Heavy and light pigs fed the Bacillus strains had higher bodyweights than pigs fed the control diet at day 28 (P<0.005 and P<0.01,respectively), as is shown in FIG. 15B.

Average daily gain for treated pigs was always higher than ADG forcontrol pigs. For Day 0 to 7 all main effects and the rep×block(P=0.0250) interaction was significant (FIG. 16). The treatment×blockinteraction is approaching significance (P=0.102). Day 7 to 28 theeffect of treatment was approaching significance (P=0.125). Day 0 to 28all main effects were significant and the effect of treatment was nearlysignificant (P=0.052). TABLE 16 Summary of the effect of Product 3 forField Trial E. Treated Control % Day 28 n = 18 n = 18 Difference %Mortality 1.5 3.5 57.1 Weight/pig (lb) 26.98 25.89 4.2 ADG (lb/day) 0-70.37 0.33 12.1 7-28 0.70 0.66 6.1 0-28 0.62 0.58 6.9 Feed:Gain 1.34 1.425.6 Gain:Feed 0.745 0.711 4.8 Feed Intake (lb) 1927.17 1826.33 5.5

Feed intake (FIG. 17) in pigs in the light weight block was higher(P<0.01) whereas intake of pigs in the other blocks was similar(Treatment×block interaction, P<0.05).

The feed:gain effect of treatment was approaching significance(P=0.125).

Referring now to FIGS. 18A and 18B, feeding the Bacillus strains reducedmortality in the high (P<0.01) and medium (P<0.01) weight blocks at day28 (Treatment×block×day interaction, P<0.05) (FIG. 18B).

Six swabs were sent from control pigs showing symptoms of E. coli edemadisease. None of the treated pigs displayed any symptoms of E. colidisease. Therefore, no swabs from treated pigs were taken. From the sixswabs 24 E. coli isolates were tested to determine their pathogenicityusing the multiplex PCR procedure. All the isolates were positive forthe F18 pili gene and Stx2e toxin gene, three isolates were positive forthe Sta and Stb enterotoxin genes (FIG. 19). Therefore, all the isolateswere positive for pathogenic E. coli, which accounted for the clinicalsigns manifested by the control pigs.

In Field Trial E, feeding Product 3 throughout the nursery periodenhanced performance by increasing ADG, pig weight, feed intake, andfeed conversion. Feeding Product 3 throughout the nursery perioddecreases mortality due to E. coli disease in Field Trial E.

It is understood that the various preferred embodiments are shown anddescribed above to illustrate different possible features of theinvention and the varying ways in which these features may be combined.Apart from combining the different features of the above embodiments invarying ways, other modifications are also considered to be within thescope of the invention. For example a single Bacillus isolate, asopposed to a combination of isolates, could be used to controlpathogenic swine E. coli.

The invention is not intended to be limited to the preferred embodimentsdescribed above, but rather is intended to be limited only by the claimsset out below. Thus, the invention encompasses all alternativeembodiments that fall literally or equivalently within the scope of theinvention.

BIBLIOGRAPHY

-   1. Dean-Nystrom, E. A. and Bartels-Morozov, D. 2001. Edema disease:    a re-emerging problem. Proceedings of the American Association of    Swine Veterinarians. 223-224.-   2. Blood, D. C. and Radostits, O. M. Veterinary Medicine 7^(th)    Edition. 637-640.-   3. Helman, R. Gayman. The Veterinary Clinics of North America Food    Animal Practice. March 2000. 117-162.-   4. Bertschinger, H. U. and Fairbrother, J. M. Diseases of Swine    8^(th) edition. 431-454.-   5. Gyles, C. 2001. Escherichia coli in Diseases of Weaned Pigs:    Biological Aspect. American Association of Swine Veterinarians.    29-41.-   6. Francis, D. H. 2004. Post-Weaning E. coli-diagnosis, treatment,    control, and its effect on subsequent growth performance. American    Association of Swine Veterinarians. 495-499.-   7. Wills, R. W. Diarrhea In Growing-Finishing Swine. The Veterinary    Clinics of North America. March 2000. 138-140.-   8. Parrott, D., Rehberger, T. and Holt, M. 2002. Molecular typing of    hemolytic Escherichia coli isolated from swine. Paper 385.    International Pig Veterinary Society.-   9. Marquardt, R. R., and et al. 1999. Passive protective effect of    egg-yolk antibodies against enterotoxigenic Escherichia coli K88+    infection in neonatal and early-weaned piglets. FEMS Immunology and    Medical Microbiology. 23. 1999. 283-288.-   10. Nagy, B., Wilson, R., Whittam, T. Genetic diversity among    Escherichia coli isolates carrying F18 genes from pigs with porcine    postweaning diarrhea and edema disease. Journal of Clinical    Microbiology. May 1999. 1642-1645.-   11. Roe, S. Protein Purification Techniques. Second edition.    172-175.

1. An isolated microorganism of the genus Bacillus that is capable of atleast one of the following: (A) inhibiting E. coli disease in animalsfed the microorganism when compared to animals not fed themicroorganism, and (B) improving performance in animals fed themicroorganism compared to animals not fed the microorganism, wherein theimprovement in performance includes an improvement in at least one ofaverage daily gain (ADG), weight, mortality, feed conversion, and feedintake.
 2. The microorganism of claim 1, wherein the microorganism isselected from the group consisting of strains 3A-P4, 15A-P4, and 22C-P1.3. The microorganism of claim 2, wherein the microorganism is strain15A-P4.
 4. A combination of microorganisms comprising at least twomicroorganisms of claim
 2. 5. The combination of claim 3, wherein thecombination comprises strains 22C-P-1 and 15A-P4.
 6. The combination ofclaim 5, wherein the combination comprises 90% of the total count ofstrain 22C-P1 and 10% of the total count of strain 15A-P4.
 7. Thecombination of claim 6, further comprising a feed, wherein thecombination has a count of 5.1×10⁸ CFU/g of feed.
 8. The combination ofclaim 5, wherein combination comprises 10% of the total count of strain22C-P1 and 90% of the total count of strain 15A-P4.
 9. The combinationof claim 8, further comprising a feed, wherein the combination has acount of 1×10⁶ CFU/g of feed.
 10. A method of feeding swine, the methodcomprising feeding to the swine at least one strain of microorganism ofthe genus Bacillus, the microorganism being capable of at least one ofthe following: (A) inhibiting E. coli disease in swine fed themicroorganism when compared to animals not fed the microorganism, and(B) improving performance of swine fed the microorganism compared toswine not fed the microorganism, wherein the improvement in performanceincludes an improvement in at least one of average daily gain (ADG),weight, mortality, feed conversion, and feed intake.
 11. The method ofclaim 10, wherein the microorganism is selected from the groupconsisting of strains 3A-P4, 15A-P4, and 22C-P1.
 12. The method of claim11, wherein the microorganism is strain 15A-P4.
 13. The method of claim11, wherein the microorganism comprises at least two strains.
 14. Themethod of claim 13, wherein the strains comprise strain 22C-P1 andstrain 15A-P4.
 15. The method of claim 14, wherein the microorganismcomprise 90% of the total count of strain 22C-P1 and 10% of the totalcount of strain 15A-P4.
 16. The method of claim 14, wherein themicroorganism comprise 10% of the total count of strain 22C-P1 and 90%of the total count of strain 15A-P4.
 17. A method of forming adirect-fed microbial, the method comprising: (a) growing, in a liquidnutrient broth, at least one microorganism of the genus Bacillus that iscapable of at least one of the following (i) inhibiting E. coli diseasein animals fed the microorganism when compared to animals not fed themicroorganism and (ii) improving performance in animals fed themicroorganism compared to animals not fed the microorganism, wherein theimprovement in performance includes an improvement in at least one ofaverage daily gain (ADG), weight, mortality, feed conversion, and feedintake; and (b) separating the microorganism from the liquid to form thedirect-fed microbial.
 18. The method of claim 17, wherein themicroorganism is selected from the group consisting of strains 3A-P4,15A-P4, and 22C-P1.
 19. The method of claim 18, wherein themicroorganism is strain 15A-P4, wherein the step of growing furthercomprises growing a second, isolated microorganism that is selected fromthe group consisting of strains 3A-P4, 15A-P4, and 22C-P1, and whereinthe second microorganism is a different strain than the firstmicroorganism.
 20. The method of claim 18, wherein the microorganism isstrain 22C-P1.
 21. The method of claim 18, further comprises combiningstrains 15A-P4 and 22C-P1.